Replies to post #235617 on Avid Bioservices Inc (CDMO)
(PS) signaling pathway is a very interesting target
and I'm convinced he is referring to Bavituximab
09/19/15 7:35 AM
09/19/15 7:45 AM
Meanwhile, the company is working to identify its first candidates for clinical testing, the first of which could be rolled out in the next two to three years, Johnson said.
Several other former Ventana executives, including recently named Chief Business Officer John Lubniewski, are leading the effort. HTG founder and former CEO Bruce Seligmann is now chief science officer, directing much of the new-product research.
..
..
High Throughput Genomics Inc. was founded in 1997 as a subsidiary of SIDDCO (Systems Integration Drug Discovery Co.), which was started by biochemist Bruce Seligmann. HTG was spun off in 2001 when SIDDCO was acquired by San Diego-based Discovery Partners International Inc.
https://www.htgmolecular.com/company/media/news/68
4. Rahul Jasuja - Noble Life Science Partners noblelsp.com/research
RJ: ”Thanks for taking my question and glad to know that PS is now being recognized by big pharma and the immunology mafia so to say. So couple of questions pertaining to how PS with checkpoint inhibitors is differentiated from the conventional checkpoints inhibitors, like the CTLA-4, PD-1, PD-L1 pathways. From the data that's been represented at ImVacS, and also in discussions they’ve had with you guys, besides blocking just PS binding to its receptors on immune cells, there is an FC- FC gamma -based effector function leading to ADCC and so on and so forth - an immune effector function that other checkpoint inhibitors do not have blocking PD-1 or blocking CTLA-4. So, you’ve got a component here that is beyond other checkpoint inhibitors, that brings in an effector function that others do not have. Looking at that aspect or looking at some of the translational data, do you think that beyond the PD-1, PD-L1 non-immunogenic tumors, there is a possibility that PS blockade will have far more effect potentially driving [ph??] antigen presentation. Any comments on that?” ..
...
4. Rahul Jasuja - Noble Life Science Partners noblelsp.com/research
RJ: ”Thanks for taking my question and glad to know that PS is now being recognized by big pharma and the immunology mafia so to say. So couple of questions pertaining to how PS with checkpoint inhibitors is differentiated from the conventional checkpoints inhibitors, like the CTLA-4, PD-1, PD-L1 pathways. From the data that's been represented at ImVacS, and also in discussions they’ve had with you guys, besides blocking just PS binding to its receptors on immune cells, there is an FC- FC gamma -based effector function leading to ADCC and so on and so forth - an immune effector function that other checkpoint inhibitors do not have blocking PD-1 or blocking CTLA-4. So, you’ve got a component here that is beyond other checkpoint inhibitors, that brings in an effector function that others do not have. Looking at that aspect or looking at some of the translational data, do you think that beyond the PD-1, PD-L1 non-immunogenic tumors, there is a possibility that PS blockade will have far more effect potentially driving [ph??] antigen presentation. Any comments on that?” ..
...
...
besides blocking just PS binding to its receptors on immune cells, there is an FC- FC gamma -based effector function leading to ADCC and so on and so forth - an immune effector function that other checkpoint inhibitors do not have blocking PD-1 or blocking CTLA-4. So, you’ve got a component here that is beyond other checkpoint inhibitors, that brings in an effector function that others do not have. Looking at that aspect or looking at some of the translational data, do you think that beyond the PD-1, PD-L1 non-immunogenic tumors, there is a possibility that PS blockade will have far more effect potentially driving [ph??] antigen presentation. Any comments on that?” ..
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |